Cost Analysis of Potential North Dakota Subterminal Systems

The purpose of this study was to analyze the cost structures associated with subterminal facilities. An economic-engineering approach was used to determine the construction and operation costs of four different sizes of subterminal facilities operating at three different plant capacities. Profitability of subterminals was determined mainly by the volume of grain handled. If a subterminal marketed enough grain, it was able to incur both decreasing average fixed and average variable costs. The larger subterminals were found to be more profitable than the smaller facilities indicating the existence of economies of size in both the fixed and variable cost components. Profitability can be dramatically increased given the availability of internal financing for the construction cost and nondepreciable fixed costs. Upper Great Plains Transportation Institute Report No.44Marketing, Agribusiness,

Feasibility of Establishing Small Livestock Slaughter Plants in North Dakota

Agribusiness,

Economic Feasibility of Utilizing Waste-Water Heat from Coal-Fired Electrical Generating Plants in Commercial Greenhouses in North Dakota

This study provides information on the economic feasibility of establishing commercial greenhouses utilizing waste-water heat in North Dakota.Production Economics, Resource /Energy Economics and Policy,

Electron Transport in Hybrid Ferromagnetic/Superconducting Nanostructures

We observe large amplitude changes in the resistance of ferromagnetic (F) wires at the onset of superconductivity of adjacent superconductors (S). New sharp peaks of large amplitude are found in the magnetoresistance of the F-wires. We discuss a new mechanism for the long-range superconducting proximity effect in F/S nanostructures based on the analysis of the topologies of actual Fermi-surfaces in ferromagnetic metals.Comment: 7 pages in LaTeX, 5 eps figures. Submitted to the Proceedings of MS200

Land use change and soil carbon pools: Evidence from a long-term silvopastoral

Multi-functional silvopastoral systems provide a wide range of services to human society including the regulation of nutrients and water in soils and the sequestration of atmospheric carbon dioxide (CO2). Although silvopastoral systems significantly contribute to enhance aboveground carbon (C) sequestration (e.g. C accumulation in woody plant biomass), their long-term effects on soil C pools are less clear. In this study we performed soil physical fractionation analyses to quantify the C pool of different aggregate fractions across three land use types including (1) silvopastoral system with ash trees (Fraxinus excelsior L.), (2) planted woodland with ash trees, and (3) permanent grassland, which were established in 1989 at Loughgall, Northern Ireland, UK. Our results show that 26 years after the conversion of permanent grassland to either silvopastoral or woodland systems, soil C (and N) stocks (0–20 cm depth) did not significantly change between the three land use types. We found, however, that permanent grassland soils were associated with significantly higher C pools (g C kg−1 soil; P 2 mm) whereas soil C pools of the micro-aggregate (53–250 μm) and silt and clay (< 53 μm) fractions were significantly higher in the silvopastoral and woodland systems (P < 0.05). A key finding of this study is that while tree planting on permanent grassland may not contribute to greater soil C stocks it may, in the long-term, increase the C pool of more stable (recalcitrant) soil micro-aggregate and silt and clay fractions, which could be more resilient to environmental change

Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.

Background In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often infected by Epstein-Barr virus, are found in tumor tissues. We postulated that the disruption of putative B-T interactions and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rituximab) could improve the clinical outcome produced by conventional chemotherapy. DESIGN AND METHODS: Twenty-five newly diagnosed patients were treated, in a phase II study, with eight cycles of rituximab + chemotherapy (R-CHOP21). Tumor infiltration, B-blasts and Epstein-Barr virus status in tumor tissue and peripheral blood were fully characterized at diagnosis and were correlated with clinical outcome. RESULTS: A complete response rate of 44% (95% CI, 24% to 65%) was observed. With a median follow-up of 24 months, the 2-year progression-free survival rate was 42% (95% CI, 22% to 61%) and overall survival rate was 62% (95% CI, 40% to 78%). The presence of Epstein-Barr virus DNA in peripheral blood mononuclear cells (14/21 patients) correlated with Epstein-Barr virus score in lymph nodes (P&lt;0.004) and the detection of circulating tumor cells (P=0.0019). Despite peripheral Epstein-Barr virus clearance after treatment, the viral load at diagnosis (&gt;100 copy/μg DNA) was associated with shorter progression-free survival (P=0.06). Conclusions We report here the results of the first clinical trial targeting both the neoplastic T cells and the microenvironment-associated CD20(+) B lymphocytes in angioimmunoblastic T-cell lymphoma, showing no clear benefit of adding rituximab to conventional chemotherapy. A strong relationship, not previously described, between circulating Epstein-Barr virus and circulating tumor cells is highlighted

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy. Lenalidomide, which has been safely combined with CHOP to treat B-cell lymphoma, has shown efficacy as a single agent in AITL treatment. We performed a multicentric phase 2 trial combining 25 mg lenalidomide daily for 14 days per cycle with 8 cycles of CHOP21 in previously untreated AITL patients aged 60 to 80 years. The primary objective was the complete metabolic response (CMR) rate at the end of treatment. Seventy-eight of the 80 patients enrolled were included in the efficacy and safety analysis. CMR was achieved in 32 (41%; 95% confidence interval [CI], 30%-52.7%) patients, which was below the prespecified CMR rate of 55% defined as success in the study. The 2-year progression-free survival (PFS) was 42.1% (95% CI, 30.9%-52.8%), and the 2-year overall survival was 59.2% (95% CI, 47.3%-69.3%). The most common toxicities were hematologic and led to treatment discontinuation in 15% of patients. This large prospective and uniform series of AITL treatment data was used to perform an integrative analysis of clinical, pathologic, biologic, and molecular data. TET2, RHOA, DNMT3A, and IDH2 mutations were present in 78%, 54%, 32%, and 22% of patients, respectively. IDH2 mutations were associated with distinct pathologic and clinical features and DNMT3A was associated with shorter PFS. In conclusion, the combination of lenalidomide and CHOP did not improve the CMR in AITL patients. This trial clarified the clinical impact of recurrent mutations in AITL. This trial was registered at www.clincialtrials.gov as #NCT01553786

A prognostic index predicting survival in transformed Waldenström macroglobulinemia

Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) usually associated with a poor prognosis. The objective of this study was to develop and validate a prognostic index for survival in transformed WM patients. Through this multicenter, international collaborative effort, we developed a scoring system based on data from 133 patients with transformed WM who were evaluated between 1995 and 2016 (training cohort). Univariate and multivariate analyses were used to propose a prognostic index with 2-year survival after transformation as an end-point. For external validation, a data set of 67 patients was used to evaluate the performance of the model (validation cohort). By multivariate analysis, three adverse covariates were identified as independent predictors of 2-year survival after transformation: elevated serum LDH (2 points), platelet count < 100 x 109/L (1 point) and any previous treatment for WM (1 point). Three risk groups were defined: low-risk (0-1 point, 24% of patients), intermediate-risk (2-3 points, 59%, hazard ratio (HR) = 3.4) and high-risk (4 points, 17%, HR = 7.5). Two-year survival rates were 81%, 47%, and 21%, respectively (P < 0.0001). This model appeared to be a better discriminant than the International Prognostic Index (IPI) and the revised IPI (R-IPI). We validated this model in an independent cohort. This easy-to-compute scoring index is a robust tool that may allow identification of groups of transformed WM patients with different outcomes and could be used for improving the development of risk-adapted treatment strategies